Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Angiogenesis. 2024 Aug;27(3):333-349. doi: 10.1007/s10456-024-09913-z. Epub 2024 Apr 6.
Sustained angiogenesis stands as a hallmark of cancer. The intricate vascular tumor microenvironment fuels cancer progression and metastasis, fosters therapy resistance, and facilitates immune evasion. Therapeutic strategies targeting tumor vasculature have emerged as transformative for cancer treatment, encompassing anti-angiogenesis, vessel normalization, and endothelial reprogramming. Growing evidence suggests the dynamic regulation of tumor angiogenesis by infiltrating myeloid cells, such as macrophages, myeloid-derived suppressor cells (MDSCs), and neutrophils. Understanding these regulatory mechanisms is pivotal in paving the way for successful vasculature-targeted cancer treatments. Therapeutic interventions aimed to disrupt myeloid cell-mediated tumor angiogenesis may reshape tumor microenvironment and overcome tumor resistance to radio/chemotherapy and immunotherapy.
持续的血管生成是癌症的一个标志。复杂的血管肿瘤微环境促进癌症的进展和转移,助长了治疗耐药性,并促进了免疫逃逸。针对肿瘤血管的治疗策略已经成为癌症治疗的一种变革,包括抗血管生成、血管正常化和内皮细胞重编程。越来越多的证据表明,浸润性髓样细胞(如巨噬细胞、髓系来源的抑制细胞(MDSCs)和中性粒细胞)对肿瘤血管生成的动态调节。了解这些调控机制对于成功进行血管靶向癌症治疗至关重要。旨在破坏髓样细胞介导的肿瘤血管生成的治疗干预措施可能会重塑肿瘤微环境并克服肿瘤对放疗/化疗和免疫治疗的耐药性。